AnaptysBio, Inc.
ANAB
$18.87
-$0.40-2.08%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 9.01M | 3.32M | 3.46M | 1.37M | 6.81M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.01M | 3.32M | 3.46M | 1.37M | 6.81M |
| Cost of Revenue | 33.53M | 30.88M | 32.92M | 34.96M | 23.37M |
| Gross Profit | -24.52M | -27.56M | -29.46M | -33.58M | -16.57M |
| SG&A Expenses | 10.28M | 10.17M | 10.68M | 10.82M | 9.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.80M | 41.05M | 43.60M | 45.78M | 32.78M |
| Operating Income | -34.80M | -37.73M | -40.14M | -44.40M | -25.97M |
| Income Before Tax | -42.22M | -37.31M | -39.85M | -44.26M | -26.39M |
| Income Tax Expenses | -4.00K | -- | -- | -- | 24.00K |
| Earnings from Continuing Operations | -42.21M | -37.31M | -39.85M | -44.26M | -26.41M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.21M | -37.31M | -39.85M | -44.26M | -26.41M |
| EBIT | -34.80M | -37.73M | -40.14M | -44.40M | -25.97M |
| EBITDA | -34.63M | -37.57M | -39.98M | -44.24M | -25.79M |
| EPS Basic | -1.59 | -1.41 | -1.50 | -1.58 | -0.93 |
| Normalized Basic EPS | -0.82 | -0.88 | -0.94 | -0.99 | -0.58 |
| EPS Diluted | -1.59 | -1.41 | -1.50 | -1.58 | -0.93 |
| Normalized Diluted EPS | -0.82 | -0.88 | -0.94 | -0.99 | -0.58 |
| Average Basic Shares Outstanding | 26.59M | 26.55M | 26.63M | 27.95M | 28.45M |
| Average Diluted Shares Outstanding | 26.59M | 26.55M | 26.63M | 27.95M | 28.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
